Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Cross Above Fifty Day Moving Average – Should You Sell?

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $28.35 and traded as high as $30.86. Lakefront Biotherapeutics American Depositary Shares shares last traded at $30.58, with a volume of 156,201 shares changing hands.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Wall Street Zen cut Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Zacks Research raised Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a research note on Monday, June 8th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Tuesday, May 26th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $36.50.

Lakefront Biotherapeutics American Depositary Shares Price Performance

The stock has a market capitalization of $2.02 billion, a price-to-earnings ratio of -21.70 and a beta of 0.25. The business has a 50 day simple moving average of $28.44 and a 200-day simple moving average of $30.87.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $0.25 EPS for the quarter, topping the consensus estimate of ($1.27) by $1.52. The company had revenue of $8.75 million for the quarter, compared to analyst estimates of $11.26 million. As a group, equities analysts predict that Lakefront Biotherapeutics American Depositary Shares will post -6.32 earnings per share for the current year.

Institutional Trading of Lakefront Biotherapeutics American Depositary Shares

A number of hedge funds have recently made changes to their positions in LKFT. Western Standard LLC bought a new stake in Lakefront Biotherapeutics American Depositary Shares in the 4th quarter valued at $1,046,000. UBS Group AG increased its position in Lakefront Biotherapeutics American Depositary Shares by 128.4% during the 4th quarter. UBS Group AG now owns 349,444 shares of the biotechnology company’s stock worth $11,427,000 after buying an additional 196,445 shares during the period. Jane Street Group LLC increased its position in Lakefront Biotherapeutics American Depositary Shares by 2,245.7% during the 1st quarter. Jane Street Group LLC now owns 110,783 shares of the biotechnology company’s stock worth $2,783,000 after buying an additional 115,946 shares during the period. Kotler Kevin acquired a new stake in shares of Lakefront Biotherapeutics American Depositary Shares during the fourth quarter worth $2,943,000. Finally, Norges Bank acquired a new stake in shares of Lakefront Biotherapeutics American Depositary Shares during the fourth quarter worth $2,943,000. 32.46% of the stock is owned by institutional investors and hedge funds.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.